Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
American Society of Clinical Oncology
Headquarters: Alexandria, VA, United States of America
Website: http://www.asco.org
Year Founded: 1964
Status: Non-biopharma
Biopharma related deals can be found by searching the organization's name in the Deals Module.
BioCentury | Feb 7, 2025
Editor's Commentary
Has interest in ADCs peaked? — a Perspective
Pfizer’s drop of a late-stage ADC this week may signal the ADC frenzy is cooling
BioCentury | Feb 7, 2025
Product Development
The radiopharma landscape takes shape in neuroendocrine tumors
Itm and Perspective’s readouts are the latest clinical advances in GEP-NETs, the first indication to put radioligand therapies on the map
BioCentury | Oct 4, 2024
Product Development
I-SPY 2.2 is working. Why aren’t others replicating the design?
Initial data show the I-SPY 2.2 design can uncover less toxic neoadjuvant breast cancer therapies
BioCentury | Oct 3, 2024
Emerging Company Profile
Mythic: Enhancing ADC payload delivery using pH engineering
Biotech engineers its antibody-drug conjugates to unbind their target upon internalization, recycling it back to the cell surface to recruit more ADCs
BioCentury | Sep 17, 2024
Deals
Pair of radiopharma deals sees Sanofi dive into 212Pb as ITM gets another 177Lu program
Deals Report: A cardiometabolic deal for Novo Nordisk and updates from BMS-Immatics, Takeda-Innate, Moderna-Carisma and more
BioCentury | Jul 24, 2024
Product Development
Benchmarking lead-212: SSTR2 test kitchen
The clinical data available for lead-212 provides initial proof-of-concept for its efficacy and safety in radioligand therapies for cancer
BioCentury | Jul 23, 2024
Product Development
Lead-212’s leading players
Decisions about manufacturing and distribution could be make-or-break for drug developers producing their own lead-212
BioCentury | Jul 22, 2024
Product Development
Battle of the alphas: lead-212 picks up speed in radiopharma
The ɑ-emitting radioisotope’s rapid decay has logistical drawbacks, but its supply could beat actinium-225’s on scale
BioCentury | Jun 19, 2024
Product Development
Clinical Report: Zentalis hold resurfaces WEE1 safety concerns
Plus data from BioNTech, MediLink, Nurix, Aerovate and more
BioCentury | Jun 18, 2024
Product Development
Tumor cell surface targets off the beaten path
Beyond the headlines at ASCO and AACR were a set of less traveled cancer targets, including neuronal proteins hijacked by solid tumors
Items per page:
1 - 10 of 3850